Giacobello Scott M. 4

What Happened

• Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics (WHWK), exercised/converted a derivative instrument covering 473,902 shares on 2026-04-01 (transaction code M). The filing shows a corresponding disposition of those 473,902 derivative shares at $0.00 (no cash proceeds reported).
• On the same date he was granted/awarded 300,677 restricted stock units (RSUs) (transaction code A) at $0.00. Under the filing footnotes, each RSU represents the contingent right to one share and vests 100% on the one‑year anniversary of the Vesting Commencement Date (April 1, 2025 → vests April 1, 2026), subject to continued service.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (timely — within the usual 2 business‑day window).
• Exercise/conversion: 473,902 shares (code M); corresponding disposition recorded at $0.00 (no cash proceeds shown).
• Award: 300,677 RSUs (code A) granted at $0.00; F1/F2 apply — each RSU = 1 share; 100% vest on 4/1/2026 if still a service provider.
• Footnote F3 describes a separate option vesting schedule (25% after one year, then monthly over four years starting 4/1/2026) for options in the plan.
• Shares owned after the transactions are not disclosed in the provided excerpt.

Context

• The filing combines a derivative exercise/conversion and an RSU grant. The $0.00 disposition indicates this was not a cash sale of shares — it appears to be a conversion/settlement or internal reclassification rather than an open‑market sale.
• RSU grants are acquisitions that can be interpreted as a form of compensation/retention; they do not necessarily signal personal market conviction.
• All explanations above are limited to what the Form 4 and its footnotes disclose; motivations are not stated.